Programmed-response cross-linked nanocarrier for multidrug-resistant ovarian cancer treatment-Reference-Cited by-同舟云学术

Programmed-response cross-linked nanocarrier for multidrug-resistant ovarian cancer treatment

Published:2023-05 Issue: Volume:357 Page:274-286
ISSN:0168-3659
Container-title:Journal of Controlled Release
language:en
Short-container-title:Journal of Controlled Release

Author:

Qu Haijing,Yang Jinfan,Li Shuaijun,Xu Ji,Zhou Xin,Xue Xiangdong,Zhang Dalin,Du Hongxu,Shen Yingbin,Ramachandran Mythili,Zheng Hongbo,Wu Yi,Ding Yifan,Wu Hao,Ma Xiaobin,Lin Tzu-Yin,Li Yuanpei

Funder

National Natural Science Foundation of China

Xi’an Jiaotong University

Natural Science Foundation of Shaanxi Provincial Department of Education

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference36 articles.

1. The promise and challenge of ovarian cancer models;Hasan;Transl. Cancer Res.,2015

2. Early stage detection and screening of ovarian cancer: a research opportunity and significant challenge for biosensor technology;De La Franier;Biosens. Bioelectron.,2019

3. Ovarian cancer mouse models: a summary of current models and their limitations;Fong;J. Ovarian Res.,2009

4. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer;Coley;Cancer Treat. Rev.,2008

5. Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis;Walsh;Br. J. Cancer,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disulfide bonds as a molecular switch of enzyme-activatable anticancer drug precise release for fluorescence imaging and enhancing tumor therapy;Talanta;2024-10

2. Dendrimers as drug delivery systems for oncotherapy: Current status of promising applications;International Journal of Pharmaceutics;2024-09

3. Advancing Ovarian Cancer Therapeutics: The Role of Targeted Drug Delivery Systems;International Journal of Nanomedicine;2024-09

4. “On/off”-switchable crosslinked PTX-nanoformulation with improved precise delivery for NSCLC brain metastases and restrained adverse reaction over nab-PTX;Biomaterials;2024-06

5. Current trends and emerging patterns in the application of nanomaterials for ovarian cancer research: a bibliometric analysis;Frontiers in Pharmacology;2024-03-08